Table 5.

Lonafarnib plus Gemcitabine Pharmacokinetic Parameter Estimates

			Lonafarnib
Lonafarnib+Gemcitabine Dose	Cycle	No. of subjects	Cmax (ng/mL)	Tmax*** (hour)	AUC (τ) (ng*hr/mL)	CL/F (nL/min)	T½ (hour)
100+750	1	4	717	5.0	5995	504	5.21
	2	3	757	4.0	6033	571	3.50
100+1000	1	3	1007	4.0	8201	577	3.80
	2	2	645	5.5	5945	370	3.79
150+750	1	2	779	5.5	5790	437	3.67
	2	1	1500	8.0	15325	163	6.68
150/100**+1000	1	6	1078	6.0	8947	413	5.57
	2	6	736	5.0	5634	440	4.68
200+600	1	5	2044	6.0	16812	594	5.32
	2	4	1885	5.0	14544	261	4.78

		Gemcitabine
Lonafarnib+Gemcitabine Dose	Day	No. of subjects	Cmax (ng/mL)	Tmax*** (hour)	AUC (τ) (ng*hr/mL)
100+750	1	4	11307	0.50	5382
	15	4	14953	0.50	7889
100+1000	1	2	10163	0.38	5075
	15	3	9797	0.25	5064
150+750	1	2	12495	0.25	5948
	15	2	11653	0.50	8005
150/100**+1000	1	7	15083	0.50	8801
	15	6	17471	0.50	10111
200+600	1	6	7934	0.38	4141
	15	7	11191	0.25	4966

C_max, peak plasma concentration, T_max, time to peak concentration, AUC(τ), area under the plasma concentration - time curve over the dosing interval (12 hours), CL/F, apparent total body clearance

^*Lonafarnib dose (mg) BID + gemcitabine dose (mg/m2)

^**Lonafarnib dose 150 mg AM, 100 mg PM

^***Median values